Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback